Veracyte
Veracyte, Inc. is a genomic diagnostics company that develops innovative diagnostic tests aimed at improving clinical outcomes for patients with various diseases, including thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Its key products include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer detection, and the Envisia Genomic Classifier to differentiate idiopathic pulmonary fibrosis from other lung diseases. Additionally, the Prosigna Breast Cancer Prognostic Gene Signature Assay assesses the risk of distant recurrence in breast cancer patients. Veracyte markets its products through specialized teams, including product specialists and medical science experts. The company has established strategic collaborations with Johnson & Johnson and Loxo Oncology to further develop and commercialize novel diagnostic tests and therapies. Originally founded as Calderome, Inc. in 2006, Veracyte rebranded in 2008 and is headquartered in South San Francisco, California.
HalioDx SAS is a Marseille-based company that specializes in designing and developing in-vitro diagnostic products in the field of immuno-oncology. Incorporated in 2014, HalioDx focuses on creating diagnostic tests that assess the immune contexture of cancers. The company offers a variety of immune scoring tests, including ImmunoscoreCC, which serves as a decision-making tool for clinicians in managing patient care by evaluating the anti-tumor immune response.
Decipher Biosciences, Inc. is a genomic information company focused on developing and commercializing clinical tests for urologic cancers. The company offers the Decipher Prostate Biopsy test, which analyzes tumor tissue to help determine appropriate treatment based on the tumor's metastatic potential. Additionally, it provides the Decipher Bladder test, a genomic subtyping tool that classifies muscle-invasive bladder cancer and identifies patients who may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences has a research and development center in Vancouver, Canada. The company is also building the GRID database, which contains over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to discover biomarkers that indicate responses to new therapies.
Allegro Diagnostics was founded in 2006 by Jerome Brody, M.D., and Avrum Spira, M.D., MSc, faculty at the Boston University School of Medicine and thought leaders in the field of pulmonology. The company is currently headquartered in Maynard, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.